Gordon Ramage

List of Publications by Year
in descending order

152 papers	14,197 citations	20817 60 h-index	20961 115 g-index
161 all docs	161 docs citations	161 times ranked	11110 citing authors

#	Article	IF	Citations
1	Standardized Method for In Vitro Antifungal Susceptibility Testing of Candida albicans Biofilms. Antimicrobial Agents and Chemotherapy, 2001, 45, 2475-2479.	3.2	667
2	Inhibition of <i>Candida albicans</i> Biofilm Formation by Farnesol, a Quorum-Sensing Molecule. Applied and Environmental Microbiology, 2002, 68, 5459-5463.	3.1	613
3	<i>Candida</i>Biofilms: an Update. Eukaryotic Cell, 2005, 4, 633-638.	3.4	612
4	Candidabiofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Research, 2006, 6, 979-986.	2.3	482
5	A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nature Protocols, 2008, 3, 1494-1500.	12.0	453
6	Detection of Prosthetic Hip Infection at Revision Arthroplasty by Immunofluorescence Microscopy and PCR Amplification of the Bacterial 16S rRNA Gene. Journal of Clinical Microbiology, 1999, 37, 3281-3290.	3.9	436
7	Our Current Understanding of Fungal Biofilms. Critical Reviews in Microbiology, 2009, 35, 340-355.	6.1	429
8	Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. Journal of Antimicrobial Chemotherapy, 2002, 49, 973-980.	3.0	403
9	Fungal Biofilm Resistance. International Journal of Microbiology, 2012, 2012, 1-14.	2.3	403
10	Denture stomatitis: a role for Candida biofilms. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2004, 98, 53-59.	1.4	338
11	The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development inCandida albicans. FEMS Microbiology Letters, 2002, 214, 95-100.	1.8	302
12	Biofilm-Forming Capability of Highly Virulent, Multidrug-Resistant<i>Candida auris</i>. Emerging Infectious Diseases, 2017, 23, 328-331.	4.3	296
13	In Vitro Activity of Caspofungin against Candida albicans Biofilms. Antimicrobial Agents and Chemotherapy, 2002, 46, 3591-3596.	3.2	276
14	The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatusÂ. Journal of Antimicrobial Chemotherapy, 2013, 68, 1486-1496.	3.0	243
15	In Vitro Pharmacodynamic Properties of Three Antifungal Agents against Preformed Candida albicans Biofilms Determined by Time-Kill Studies. Antimicrobial Agents and Chemotherapy, 2002, 46, 3634-3636.	3.2	231
16	Hsp90 Governs Dispersion and Drug Resistance of Fungal Biofilms. PLoS Pathogens, 2011, 7, e1002257.	4.7	231
17	Development of a simple model for studying the effects of antifungal agents on multicellular communities of Aspergillus fumigatus. Journal of Medical Microbiology, 2007, 56, 1205-1212.	1.8	222
18	Formation of Propionibacterium acnes biofilms on orthopaedic biomaterials and their susceptibility to antimicrobials. Biomaterials, 2003, 24, 3221-3227.	11.4	218

#	Article	IF	Citations
19	Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infectionâ€”Scotland, 2012â€“2013. Clinical Microbiology and Infection, 2016, 22, 87-93.	6.0	188
20	Propionibacterium acnes Types I and II Represent Phylogenetically Distinct Groups. Journal of Clinical Microbiology, 2005, 43, 326-334.	3.9	187
21	Pseudomonas aeruginosa and their small diffusible extracellular molecules inhibit Aspergillus fumigatusâ€ƒbiofilm formation. FEMS Microbiology Letters, 2010, 313, 96-102.	1.8	184
22	Oral candidosis â€“ Clinical challenges of a biofilm disease. Critical Reviews in Microbiology, 2011, 37, 328-336.	6.1	153
23	Transcriptome Assembly and Profiling of <i>Candida auris</i> Reveals Novel Insights into Biofilm-Mediated Resistance. MSphere, 2018, 3, .	2.9	151
24	Extracellular DNA Release Acts as an Antifungal Resistance Mechanism in Mature Aspergillus fumigatus Biofilms. Eukaryotic Cell, 2013, 12, 420-429.	3.4	137
25	Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump Activity. Antimicrobial Agents and Chemotherapy, 2011, 55, 2092-2097.	3.2	135
26	CAMP factor homologues in Propionibacterium acnes: a new protein family differentially expressed by types I and II. Microbiology (United Kingdom), 2005, 151, 1369-1379.	1.8	133
27	Candida albicans Mycofilms Support Staphylococcus aureus Colonization and Enhances Miconazole Resistance in Dual-Species Interactions. Frontiers in Microbiology, 2017, 8, 258.	3.5	128
28	Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. International Journal of Antimicrobial Agents, 2009, 33, 374-378.	2.5	126
29	Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity. BMC Microbiology, 2014, 14, 182.	3.3	124
30	Rapid Colorimetric Assay for Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2004, 48, 1879-1881.	3.2	117
31	Dentures are a Reservoir for Respiratory Pathogens. Journal of Prosthodontics, 2016, 25, 99-104.	3.7	116
32	Aspergillus biofilms: clinical and industrial significance. FEMS Microbiology Letters, 2011, 324, 89-97.	1.8	114
33	One step closer to understanding the role of bacteria in diabetic foot ulcers: characterising the microbiome of ulcers. BMC Microbiology, 2016, 16, 54.	3.3	113
34	Antimicrobial Susceptibility of Bacteria Isolated from Orthopedic Implants following Revision Hip Surgery. Antimicrobial Agents and Chemotherapy, 1998, 42, 3002-3005.	3.2	111
35	The characteristics of<i>Aspergillus fumigatus</i>mycetoma development: is this a biofilm?. Medical Mycology, 2009, 47, S120-S126.	0.7	109
36	Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. Journal of Antimicrobial Chemotherapy, 2008, 62, 1281-1284.	3.0	105

#	Article	IF	Citations
37	Selected dietary (poly)phenols inhibit periodontal pathogen growth and biofilm formation. Food and Function, 2015, 6, 719-729.	4.6	100
38	<i>Candida albicans</i> biofilms and polymicrobial interactions. Critical Reviews in Microbiology, 2021, 47, 91-111.	6.1	96
39	Biofilm formation by Scottish clinical isolates of Staphylococcus aureus. Journal of Medical Microbiology, 2008, 57, 1018-1023.	1.8	88
40	Combined Antifungal Resistance and Biofilm Tolerance: the Global Threat of Candida auris. MSphere, 2019, 4, .	2.9	87
41	Utilising polyphenols for the clinical management of Candida albicans biofilms. International Journal of Antimicrobial Agents, 2014, 44, 269-273.	2.5	86
42	Antifungal Combinations against Candida albicans Biofilms In Vitro. Antimicrobial Agents and Chemotherapy, 2003, 47, 3657-3659.	3.2	84
43	Surface disinfection challenges for Candida auris: an in-vitro study. Journal of Hospital Infection, 2018, 98, 433-436.	2.9	84
44	The Oral Microbiome of Denture Wearers Is Influenced by Levels of Natural Dentition. PLoS ONE, 2015, 10, e0137717.	2.5	82
45	Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms. Microbial Cell, 2018, 5, 300-326.	3.2	81
46	Strength in numbers: antifungal strategies against fungal biofilms. International Journal of Antimicrobial Agents, 2014, 43, 114-120.	2.5	79
47	Quorum-Sensing Mutations Affect Attachment and Stability of Burkholderia cenocepacia Biofilms. Applied and Environmental Microbiology, 2005, 71, 5208-5218.	3.1	77
48	Polymicrobial<i>Candida</i>biofilms: friends and foe in the oral cavity. FEMS Yeast Research, 2015, 15, fov077.	2.3	76
49	Influence of Tigecycline on Expression of Virulence Factors in Biofilm-Associated Cells of Methicillin-Resistant <i>Staphylococcus aureus</i>. Antimicrobial Agents and Chemotherapy, 2010, 54, 380-387.	3.2	71
50	<i>Aspergillus fumigatus</i>enhances elastase production in<i>Pseudomonas aeruginosa</i>co-cultures. Medical Mycology, 2015, 53, 645-655.	0.7	69
51	<scp>H</scp>igh osmolarity glycerol response <scp>PtcB</scp> phosphatase is important for <scp><i>A</i></scp><i>spergillus fumigatus</i> virulence. Molecular Microbiology, 2015, 96, 42-54.	2.5	69
52	Development of an in vitroperiodontal biofilm model for assessing antimicrobial and host modulatory effects of bioactive molecules. BMC Oral Health, 2014, 14, 80.	2.3	68
53	Community Development between<i>Porphyromonas gingivalis</i>and<i>Candida albicans</i>Mediated by InlJ and Als3. MBio, 2018, 9, .	4.1	68
54	Recent Advances on Filamentous Fungal Biofilms for Industrial Uses. Applied Biochemistry and Biotechnology, 2012, 167, 1235-1253.	2.9	67

#	Article	IF	Citations
55	The comparative efficacy of antiseptics against Candida auris biofilms. International Journal of Antimicrobial Agents, 2018, 52, 673-677.	2.5	67
56	The Aspergillus fumigatus sitA Phosphatase Homologue Is Important for Adhesion, Cell Wall Integrity, Biofilm Formation, and Virulence. Eukaryotic Cell, 2015, 14, 728-744.	3.4	66
57	Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	66
58	Antifungal, Cytotoxic, and Immunomodulatory Properties of Tea Tree Oil and Its Derivative Components: Potential Role in Management of Oral Candidosis in Cancer Patients. Frontiers in Microbiology, 2012, 3, 220.	3.5	65
59	Acetylcholine Protects against Candida albicans Infection by Inhibiting Biofilm Formation and Promoting Hemocyte Function in a Galleria mellonella Infection Model. Eukaryotic Cell, 2015, 14, 834-844.	3.4	62
60	Clinical associations between IL-17 family cytokines and periodontitis and potential differential roles for IL-17A and IL-17E in periodontal immunity. Inflammation Research, 2014, 63, 1001-1012.	4.0	61
61	A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients. Frontiers in Microbiology, 2016, 7, 915.	3.5	60
62	The Anti-Adhesive Effect of Curcumin on Candida albicans Biofilms on Denture Materials. Frontiers in Microbiology, 2017, 8, 659.	3.5	60
63	Reducing the Incidence of Denture Stomatitis: Are Denture Cleansers Sufficient?. Journal of Prosthodontics, 2010, 19, 252-257.	3.7	59
64	Inhibition on Candida albicans biofilm formation using divalent cation chelators (EDTA). Mycopathologia, 2007, 164, 301-306.	3.1	57
65	Denture Stomatitis: Causes, Cures and Prevention. Primary Dental Journal, 2017, 6, 46-51.	0.6	55
66	Extracellular DNA release confers heterogeneity in Candida albicans biofilm formation. BMC Microbiology, 2014, 14, 303.	3.3	53
67	A novel metabolomic approach used for the comparison of Staphylococcus aureus planktonic cells and biofilm samples. Metabolomics, 2016, 12, 75.	3.0	53
68	Minimum information guideline for spectrophotometric and fluorometric methods to assess biofilm formation in microplates. Biofilm, 2020, 2, 100010.	3.8	50
69	Liposomal Amphotericin B Displays Rapid Dose-Dependent Activity against Candida albicans Biofilms. Antimicrobial Agents and Chemotherapy, 2013, 57, 2369-2371.	3.2	49
70	Pathogenesis of Fungal Infections in Cystic Fibrosis. Current Fungal Infection Reports, 2016, 10, 163-169.	2.6	49
71	Candida auris: A Decade of Understanding of an Enigmatic Pathogenic Yeast. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlo	3.5	49
72	Commercial mouthwashes are more effective than azole antifungals against Candida albicans biofilms in vitro. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2011, 111, 456-460.	1.4	48

#	Article	IF	Citations
73	Viable Compositional Analysis of an Eleven Species Oral Polymicrobial Biofilm. Frontiers in Microbiology, 2016, 7, 912.	3.5	47
74	Hydrolytic Enzyme Production is Associated with Candida Albicans Biofilm Formation from Patients with Type 1 Diabetes. Mycopathologia, 2010, 170, 229-235.	3.1	46
75	In Vitro Candida albicans Biofilm Induced Proteinase Activity and SAP8 Expression Correlates with In Vivo Denture Stomatitis Severity. Mycopathologia, 2012, 174, 11-19.	3.1	46
76	Assessing the impact of curcumin on dualâ€species biofilms formed by <i>Streptococcus mutans</i> and <i>Candida albicans</i>. MicrobiologyOpen, 2019, 8, e937.	3.0	46
77	Candida auris Phenotypic Heterogeneity Determines Pathogenicity <i>In Vitro</i>. MSphere, 2020, 5, .	2.9	46
78	RNAseq reveals hydrophobins that are involved in the adaptation of Aspergillus nidulans to lignocellulose. Biotechnology for Biofuels, 2016, 9, 145.	6.2	43
79	Activity of Pyocin S2 against Pseudomonas aeruginosa Biofilms. Antimicrobial Agents and Chemotherapy, 2012, 56, 1599-1601.	3.2	41
80	The Clinical Importance of Fungal Biofilms. Advances in Applied Microbiology, 2013, 84, 27-83.	2.4	41
81	FormaciÃ³n de biopelÃculas de Candida albicans en condiciones de flujo utilizando un aparato de Robbins modificado mejorado. Revista Iberoamericana De Micologia, 2008, 25, 37-40.	0.9	40
82	A novel targeted/untargeted GC-Orbitrap metabolomics methodology applied to Candida albicans and Staphylococcus aureus biofilms. Metabolomics, 2016, 12, 189.	3.0	39
83	Integrating Candida albicans metabolism with biofilm heterogeneity by transcriptome mapping. Scientific Reports, 2016, 6, 35436.	3.3	39
84	Polymicrobial oral biofilm models: simplifying the complex. Journal of Medical Microbiology, 2019, 68, 1573-1584.	1.8	39
85	Are we any closer to beating the biofilm: novel methods of biofilm control. Current Opinion in Infectious Diseases, 2010, 23, 560-566.	3.1	37
86	Novel nanocarrier of miconazole based on chitosan-coated iron oxide nanoparticles as a nanotherapy to fight Candida biofilms. Colloids and Surfaces B: Biointerfaces, 2020, 192, 111080.	5.0	37
87	Some biological features of Candida albicans mutants for genes coding fungal proteins containing the CFEM domain. FEMS Yeast Research, 2011, 11, 273-284.	2.3	36
88	Gaining Insights from Candida Biofilm Heterogeneity: One Size Does Not Fit All. Journal of Fungi (Basel, Switzerland), 2018, 4, 12.	3.5	36
89	Carbohydrate Derived Fulvic Acid: An in vitro Investigation of a Novel Membrane Active Antiseptic Agent Against Candida albicans Biofilms. Frontiers in Microbiology, 2012, 3, 116.	3.5	35
90	Investigating the biological properties of carbohydrate derived fulvic acid (CHD-FA) as a potential novel therapy for the management of oral biofilm infections. BMC Oral Health, 2013, 13, 47.	2.3	35

#	Article	IF	Citations
91	Recurrent Vulvovaginal Candidiasis: a Dynamic Interkingdom Biofilm Disease of <i>Candida</i> and <i>Lactobacillus</i>. MSystems, 2021, 6, e0062221.	3.8	35
92	Development and characterisation of a novel three-dimensional inter-kingdom wound biofilm model. Biofouling, 2016, 32, 1259-1270.	2.2	34
93	Biofilm-stimulated epithelium modulates the inflammatory responses in co-cultured immune cells. Scientific Reports, 2019, 9, 15779.	3.3	33
94	A Comparative In Vitro Study of Two Denture Cleaning Techniques as an Effective Strategy for Inhibiting <i>Candida albicans</i> Biofilms on Denture Surfaces and Reducing Inflammation. Journal of Prosthodontics, 2012, 21, 516-522.	3.7	31
95	A Novel Antifungal Is Active against Candida albicans Biofilms and Inhibits Mutagenic Acetaldehyde Production In Vitro. PLoS ONE, 2014, 9, e97864.	2.5	31
96	Implications of Antimicrobial Combinations in Complex Wound Biofilms Containing Fungi. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	31
97	[42] Detection of prosthetic joint biofilm infection using immunological and molecular techniques. Methods in Enzymology, 1999, 310, 566-576.	1.0	30
98	Susceptibility to Melaleuca alternifolia (tea tree) oil of yeasts isolated from the mouths of patients with advanced cancer. Oral Oncology, 2006, 42, 487-492.	1.5	30
99	Evaluating Streptococcus mutans Strain Dependent Characteristics in a Polymicrobial Biofilm Community. Frontiers in Microbiology, 2018, 9, 1498.	3.5	30
100	Mechanical biofilm disruption causes microbial and immunological shifts in periodontitis patients. Scientific Reports, 2021, 11, 9796.	3.3	30
101	A curcumin-sophorolipid nanocomplex inhibits Candida albicans filamentation and biofilm development. Colloids and Surfaces B: Biointerfaces, 2021, 200, 111617.	5.0	29
102	New strategic insights into managing fungal biofilms. Frontiers in Microbiology, 2015, 6, 1077.	3.5	28
103	Multi-omics tools for studying microbial biofilms: current perspectives and future directions. Critical Reviews in Microbiology, 2020, 46, 759-778.	6.1	27
104	Fungi at the Scene of the Crime: Innocent Bystanders or Accomplices in Oral Infections?. Current Clinical Microbiology Reports, 2018, 5, 190-200.	3.4	25
105	Candida albicans as an Essential â€œKeystoneâ€• Component within Polymicrobial Oral Biofilm Models?. Microorganisms, 2021, 9, 59.	3.6	23
106	Chitosan Ameliorates Candida auris Virulence in a Galleria mellonella Infection Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	22
107	Candida albicans biofilm heterogeneity does not influence denture stomatitis but strongly influences denture cleansing capacity. Journal of Medical Microbiology, 2017, 66, 54-60.	1.8	22
108	Commercial mouthwashes are ineffective against oral MRSA biofilms. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 115, 624-629.	0.4	21

#	Article	IF	Citations
109	Materials-driven fibronectin assembly on nanoscale topography enhances mesenchymal stem cell adhesion, protecting cells from bacterial virulence factors and preventing biofilm formation. Biomaterials, 2022, 280, 121263.	11.4	21
110	Mitogen activated protein kinases (MAPK) and protein phosphatases are involved in Aspergillus fumigatus adhesion and biofilm formation. Cell Surface, 2018, 1, 43-56.	3.0	20
111	Impact of frequency of denture cleaning on microbial and clinical parameters â€“ a bench to chairside approach. Journal of Oral Microbiology, 2019, 11, 1538437.	2.7	20
112	Fungal Biofilms in Human Disease. Advances in Experimental Medicine and Biology, 2015, 831, 11-27.	1.6	18
113	Efficacy of rifampicin combination therapy for the treatment of enterococcal infections assessed in vivo using a Galleria mellonella infection model. International Journal of Antimicrobial Agents, 2017, 49, 507-511.	2.5	18
114	Non-typeable <i>Haemophilus influenzae</i> chronic colonization in chronic obstructive pulmonary disease (COPD). Critical Reviews in Microbiology, 2021, 47, 192-205.	6.1	18
115	The Influence of Glycated Hemoglobin on the Cross Susceptibility Between Type 1 Diabetes Mellitus and Periodontal Disease. Journal of Periodontology, 2015, 86, 1249-1259.	3.4	17
116	Aspergillus Biofilms in Human Disease. Advances in Experimental Medicine and Biology, 2016, 931, 1-11.	1.6	17
117	Repurposing Pilocarpine Hydrochloride for Treatment of Candida albicans Infections. MSphere, 2019, 4, .	2.9	17
118	Prior in vitro exposure to voriconazole confers resistance to amphotericin B in Aspergillus fumigatus biofilms. International Journal of Antimicrobial Agents, 2015, 46, 342-345.	2.5	16
119	Candida albicans Biofilm Heterogeneity and Tolerance of Clinical Isolates: Implications for Secondary Endodontic Infections. Antibiotics, 2019, 8, 204.	3.7	16
120	Comparing apples and oranges: considerations for quantifying candidal biofilms with XTT [2,3-bis(2-methoxy-4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide] and the need for standardized testing. Journal of Medical Microbiology, 2016, 65, 259-260.	1.8	16
121	Interkingdom interactions on the denture surface: Implications for oral hygiene. Biofilm, 2019, 1, 100002.	3.8	15
122	Nanoimprinting of biomedical polymers reduces candidal physical adhesion. Nanomedicine: Nanotechnology, Biology, and Medicine, 2018, 14, 1045-1049.	3.3	13
123	A nanocarrier system that potentiates the effect of miconazole within different interkingdom biofilms. Journal of Oral Microbiology, 2020, 12, 1771071.	2.7	12
124	Effects of Antifungal Carriers Based on Chitosan-Coated Iron Oxide Nanoparticles on Microcosm Biofilms. Antibiotics, 2021, 10, 588.	3.7	12
125	Population genetics and microevolution of clinical <i>Candida glabrata</i> reveals recombinant sequence types and hyper-variation within mitochondrial genomes, virulence genes, and drug targets. Genetics, 2022, 221, .	2.9	11
126	In Vitro Effect of Porphyromonas gingivalis Methionine Gamma Lyase on Biofilm Composition and Oral Inflammatory Response. PLoS ONE, 2016, 11, e0169157.	2.5	10

#	Article	IF	Citations
127	Investigating the Transcriptome of Candida albicans in a Dual-Species Staphylococcus aureus Biofilm Model. Frontiers in Cellular and Infection Microbiology, 2021, 11, 791523.	3.9	10
128	Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models. Frontiers in Microbiology, 2017, 8, 2585.	3.5	9
129	Dyeing fungi: amphotericin B based fluorescent probes for multiplexed imaging. Chemical Communications, 2021, 57, 1899-1902.	4.1	9
130	Identification and Phenotypic Characterization of Hsp90 Phosphorylation Sites That Modulate Virulence Traits in the Major Human Fungal Pathogen Candida albicans. Frontiers in Cellular and Infection Microbiology, 2021, 11, 637836.	3.9	9
131	Development of a high throughput and low cost model for the study of semi-dry biofilms. Biofouling, 2020, 36, 403-415.	2.2	9
132	Assessing the inflammatory response to in vitro polymicrobial wound biofilms in a skin epidermis model. Npj Biofilms and Microbiomes, 2022, 8, 19.	6.4	9
133	Candida albicans and Enterococcus faecalis biofilm frenemies: When the relationship sours. Biofilm, 2022, 4, 100072.	3.8	8
134	A sticky situation: extracellular DNA shapes Aspergillus fumigatus biofilms. Frontiers in Microbiology, 2013, 4, 159.	3.5	7
135	Comparison of Three Endodontic Irrigant Regimens against Dual-Species Interkingdom Biofilms: Considerations for Maintaining the Status Quo. Antibiotics, 2020, 9, 634.	3.7	7
136	The systemic inflammatory response following hand instrumentation versus ultrasonic instrumentationâ€"A randomized controlled trial. Journal of Clinical Periodontology, 2020, 47, 1087-1097.	4.9	7
137	The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiology Letters, 2002, 214, 95-100.	1.8	7
138	Attachment of Candida albicans to denture base acrylic resin processed by three different methods. International Journal of Prosthodontics, 2009, 22, 488-9.	1.7	7
139	Small molecule based anti-virulence approaches against <i>Candida albicans</i> infections. Critical Reviews in Microbiology, 2022, 48, 743-769.	6.1	7
140	Candida albicansFungaemia following Traumatic Urethral Catheterisation in a Paraplegic Patient with Diabetes Mellitus and Candiduria Treated by Caspofungin. Case Reports in Infectious Diseases, 2013, 2013, 1-6.	0.5	6
141	Assessing the Bioactive Profile of Antifungal-Loaded Calcium Sulfate against Fungal Biofilms. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	6
142	An In Vitro Evaluation of Denture Cleansing Regimens against a Polymicrobial Denture Biofilm Model. Antibiotics, 2022, 11, 113.	3.7	6
143	Chitosan Enhances the Anti-Biofilm Activity of Biodentine against an Interkingdom Biofilm Model. Antibiotics, 2021, 10, 1317.	3.7	5
144	Filling the Void: An Optimized Polymicrobial Interkingdom Biofilm Model for Assessing Novel Antimicrobial Agents in Endodontic Infection. Microorganisms, 2020, 8, 1988.	3.6	4

#	Article	IF	Citations
145	Investigating Dual-Species Candida auris and Staphylococcal Biofilm Antiseptic Challenge. Antibiotics, 2022, 11, 931.	3.7	4
146	The application of phenotypic microarray analysis to anti-fungal drug development. Journal of Microbiological Methods, 2017, 134, 35-37.	1.6	3
147	Cell Viability Assays for Candida auris. Methods in Molecular Biology, 2022, , 129-153.	0.9	3
148	Screening the Tocriscreenâ„¢ bioactive compound library in search for inhibitors ofÂ <i>Candida</i> Âbiofilm formation. Apmis, 0, , .	2.0	3
149	Candida Virulence Factors. , 2015, , 7-19.		1
150	Reduction of Pseudomonas aeruginosa biofilm formation through the application of nanoscale vibration. Journal of Bioscience and Bioengineering, 2020, 129, 379-386.	2.2	1
151	Antifungal loaded calcium sulfate beads as a potential therapeutic in combating Candida auris. Antimicrobial Agents and Chemotherapy, 2021, , AAC0171321.	3.2	0
152	Clinical Implications ofÂInterkingdom Fungal and Bacterial Biofilms. , 2017, , 33-68.		0